_edited.png)
How to Launch a Hemp or Cannabinoid Product in India: From Idea to Manufacturing
By Vikramm Mitra, Founder, Delta Botanicals & Research
Last updated: 29 September 2026
Key takeaways
Launching a hemp or cannabinoid product in India is a sequence of decisions, not a manufacturer search.
Classification comes first. What your product is determines which ingredients, claims, manufacturing capabilities and regulatory requirements may apply.
Decide whether you need a white-label product, a modified existing formulation or a proprietary formulation before spending heavily on development.
Raw-material sourcing can make or break commercial viability. A prototype ingredient is of little use if it cannot be sourced consistently at scale.
A manufacturer's MOQ is not simply a production number. It is a working-capital decision.
A compliant formulation can still become a problem if the packaging, label, website or advertising makes claims the product category cannot support.
Product first. Pathway second. Manufacturer third.
“We want to launch a CBD oil in India. Can you connect us with a manufacturer?”
It is one of the most common kinds of enquiries we receive.
And very often, it begins with the wrong question.
Before you search for a manufacturer, you need to know what exactly you are asking that manufacturer to make.
What is the product?
What will it contain?
Who is it intended for?
What is it meant to do?
What will the brand say about it?
Under which regulatory pathway could it potentially be manufactured and sold?
Where will the hemp- or cannabinoid-containing material come from?
Do you need an existing formulation, a modified formulation or something proprietary?
What batch size makes commercial sense?
And what evidence should follow the ingredients and the finished product?
Only after those questions have been answered does: “Who should manufacture it"
become the right question.
That is why launching a hemp or cannabinoid product in India should not begin as a manufacturer search.
It should begin as a product-development process.
The 10-Step Framework for Launching a Hemp or Cannabinoid Product in India
Each stage has a gate. Do not move to the next stage simply because the previous one looks exciting.
Step | Decision | Move forward when you can say… |
1 | Product idea | We can describe the format, consumer, purpose and positioning clearly. |
2 | Classification and claims | We understand the likely regulatory category and what still needs confirmation. |
3 | Development model | We know whether we are white-labelling, modifying an existing formula or developing a proprietary product—and why. |
4 | Formula and specification | A competent manufacturer could evaluate and quote the project from our brief. |
5 | Ingredient sourcing | The critical inputs are documented and can realistically be obtained at commercial scale. |
6 | Manufacturer selection | The manufacturing partner is suitable for the product category, technically capable and commercially workable. |
7 | Pilot, testing and stability | We can produce the product consistently against an agreed specification. |
8 | Packaging and labelling | The pack protects the product and the label aligns with the applicable product category. |
9 | Commercial economics | The project still makes sense at the manufacturer's MOQ and under a weak sell-through scenario. |
10 | Launch | The label, website, advertising, sales material and distribution strategy tell the same compliant story. |
We deliberately do not attach a universal timeline to this framework.
A hemp-seed food, an Ayurvedic formulation, a topical, a cannabinoid-containing medicinal product and an imported finished formulation are not the same project.
Development and approval requirements can vary substantially depending on what is actually being built.
Patterns we see repeatedly
A founder develops a prototype around an ingredient that later cannot be sourced consistently.
A formulation may be acceptable, but the brand's website starts making claims the product category cannot support.
A manufacturer quotes an attractive per-unit price, but the MOQ absorbs most of the founder's available working capital.
Or a product is designed first and the regulatory pathway is investigated afterwards.
These are not isolated manufacturing problems.
They are project-design problems.
1. Define What You Are Actually Launching
“I want to launch a hemp product” tells us almost nothing.
The proposed product could be:
hemp seed, hemp-seed oil, hemp flour or another qualifying hemp-seed food;
an Ayurvedic formulation involving Cannabis/Vijaya/Bhanga;
a cannabinoid-containing oral oil;
a topical or personal-care product;
a capsule or tablet;
a botanical or drug product;
a raw extract or ingredient supplied B2B;
an imported finished formulation.
These should not automatically be placed under one regulatory label simply because they are connected to Cannabis sativa.
That distinction is particularly important in food.
FSSAI has specifically standardised hemp seeds and certain seed products, including hemp seed, oil extracted from hemp seeds and hemp-seed flour. Its rules also impose cannabinoid and labelling conditions.
The framework does not operate as a blanket approval to add extracted cannabinoids to ordinary foods and market them as “CBD foods.” FSSAI also restricts CBD-related claims and certain cannabis imagery on qualifying hemp-seed foods.
Before development begins, you should therefore be able to define: Product format + target consumer + intended purpose + ingredients + intended claims + market positioning.
If those six things are still fluid, you are probably not yet ready to ask a manufacturer for a commercial quote.
2. Classify the Product Before You Build It
India does not offer one universal “CBD licence” that solves every hemp- or cannabinoid-product launch.
The applicable pathway depends on the material, activity, intended use, claims, product category and sometimes the state in which an activity occurs.
Different frameworks may become relevant depending on what you are developing.
Proposed product | Regulatory question to settle first |
Hemp-seed food | Does the ingredient and finished product fall within the FSSAI hemp-seed framework and meet its composition and labelling requirements? |
Ayurvedic/Vijaya formulation | Is the product being developed within an appropriate Ayurvedic drug pathway, and what permissions or review apply to the cannabis-containing input? |
Cannabinoid-containing oral oil | What is the intended use and claim, what exactly is the cannabinoid source, and under which product category could it lawfully fall? Do not assume food or nutraceutical status. |
Topical/personal-care product | Is it a cosmetic or does its composition/positioning/claim move it toward a drug pathway? |
Capsule/tablet | What is the product legally intended to be? Do not assume a cannabinoid-containing capsule automatically qualifies as a nutraceutical. |
Raw extract/ingredient | What material is being sourced, possessed, processed or supplied, for what authorised onward use, and which permissions apply to those activities? |
Drug/phytopharmaceutical project | Does the proposed product fall within a drug-development route requiring the relevant CDSCO pathway, evidence and approvals? |
Imported finished product | Can that specific formulation legally enter and be marketed in India in its existing form, or is localisation required? |
The Ministry of Ayush's regulatory framework recognises Ayurvedic drug manufacture and specific controls around substances such as Bhanga (Cannabis sativa). Ministry reporting has also documented additional scrutiny of ASU formulations containing Bhang.
Separately, CDSCO maintains a distinct framework for new and phytopharmaceutical drugs, with requirements around product characterisation, evidence, quality and regulatory approval.
The point is not that every cannabinoid product belongs to one of these pathways.
The point is the opposite: You should establish the pathway before building the product around an assumed category.
Regulatory strategy is not something you add after formulation. It is one of the inputs into formulation.
If you do not yet know which pathway your concept belongs to, you do not have a manufacturing problem yet.
You have a product-scoping problem.
3. White Label, Modified Formula or Proprietary Product?
Once the product and pathway are clearer, the next question is how much product development you actually need.
Many founders automatically assume that a “custom formulation” is more sophisticated and therefore better.
Not necessarily.
White label
The manufacturer already has a formulation and you launch it under your brand, subject to the relevant commercial and regulatory arrangements.
This may offer: faster development, lower initial development cost and potentially lower complexity, but usually with less differentiation.
It can make sense for a founder validating a category before committing substantial capital.
Modified existing formulation
A manufacturer or development partner has a base formulation, but modifications are made around parameters such as concentration, complementary ingredients, flavour, dosage form or packaging.
This can create a middle ground between speed and differentiation.
Custom or proprietary formulation
The product is developed around a specific brief, specification, positioning or IP strategy.
This may provide greater differentiation, but it can also mean more development work, testing, documentation, cost and time.
Before calling any formula “proprietary”, clarify:
Who owns it?
Who owns modifications?
Can the manufacturer sell the same formula to somebody else?
Can you move production to another manufacturer?
What happens to the formula if the commercial relationship ends?
“White label” and “private label” are also used inconsistently across the industry.
Do not rely on the label. Read the agreement.
Custom does not automatically mean better.
The right model depends on what the business is trying to prove.
4. Turn the Idea Into a Product Specification
“I want a premium cannabinoid oil for evening use.”
That is a product idea.
It is not yet a manufacturable specification.
A development brief may need to establish questions such as:
Dosage form
Target cannabinoid profile
Concentration or strength
Carrier or base
Complementary ingredients
Serving or dose-delivery mechanism
Taste and sensory requirements
Pack format
Formula-pack compatibility
Shelf-life target
Target consumer
Intended positioning and claims
Target cost of goods
This is also where compliance and commercial strategy meet.
Suppose your target consumer price demands that the finished unit leave the factory below a certain cost. That becomes part of the development brief.
Suppose your intended positioning depends on a claim that the proposed regulatory category may not support.
That changes the brief.
Or lets say an ingredient works scientifically but cannot be sourced consistently in India at your target price.
That changes the brief again.
A good product specification is not simply:
10% CBD oil in a 30 ml bottle.
It should be detailed enough that a competent technical and manufacturing partner can understand what is being built, how success will be measured and what constraints must be respected.
5. Raw Material and Cannabinoid Sourcing
A finished product is only as defensible as the material going into it.
For hemp- or cannabinoid-containing inputs, sourcing due diligence can include:
origin and source
plant material or starting material
manufacturing/extraction route where relevant
cannabinoid profile
specification
certificate of analysis
batch-to-batch consistency
microbiology
heavy metals
pesticides where relevant
residual solvents where relevant
traceability
shelf life
supplier documentation
MOQ
commercial availability
lead time
ability to continue supplying at scale
This is where many attractive prototypes quietly become poor businesses. You may develop a beautiful sample using 500 grams of a specialist input. But what happens when the commercial order requires 50 kilograms?
Can the supplier provide it?
At the same specification?
With the same paperwork?
At a commercially acceptable price?
Within the production schedule?
A formulation that depends on an unreliable ingredient is not a commercial formulation.
This is why ingredient sourcing should be resolved during development, not after a product has already been approved internally by the brand.
6. How to Choose a Hemp or Cannabinoid Manufacturer in India
Searching “CBD manufacturer India” will give you manufacturers. That does not automatically tell you which one fits your project. The founder needs a buyer-side due-diligence framework.
Question | What to examine |
Regulatory fit | Is the facility appropriately licensed and suitable for the actual product category? |
Dosage-form capability | Can it competently produce the required oil, capsule, tablet, topical or other format? |
Ingredient capability | Can the facility lawfully source, receive and handle the proposed inputs? |
Formulation capability | Is it merely offering catalogue products, or can it undertake genuine development work? |
Pilot capability | Can smaller validation batches be produced before a full commercial run? |
MOQ | Does the minimum run make sense for your available capital and realistic sell-through? |
QA/QC | What quality-control and batch-release systems are used? |
Documentation | What specifications, COAs, batch records and stability information can be provided? |
Packaging capability | Can the site accurately fill, close, seal and handle your selected packaging? |
IP/confidentiality | Who owns the formula? Is there an NDA? Does exclusivity exist? |
Capacity | Can the facility scale if demand increases? |
Lead time | How long are development, procurement and commercial production cycles? |
Commercial terms | Development fees, deposits, payment terms, MOQ and cancellation conditions |
Change control | What happens if a raw material, specification or process has to change? |
A GMP certificate or other credential may matter, but it is not, by itself, proof that the manufacturer fits your specific product.
Manufacturer or supplier red flags
Be careful when somebody:
promises that “no licence is required” before properly understanding your product;
will not provide relevant specifications or COAs;
guarantees an unrealistically fixed launch date irrespective of the regulatory pathway;
quotes a final commercial price before receiving a meaningful specification;
is unclear about formula ownership;
or
encourages aggressive claims but cannot explain the evidence or regulatory basis behind them.
Where Delta fits
Delta sits on the project-development and buyer side of the table. We do not need to pretend every product should be manufactured by the same factory.
The job is to determine what should be built, identify the inputs and capabilities it requires, assess whether the economics work, and then identify manufacturing partners that fit that specific project.
That distinction matters.
A manufacturer's job is to manufacture.
Your job is to make sure you have chosen the right thing to manufacture.
7. Prototype, Pilot, Testing and Stability
A commercial product should not normally jump straight from an idea to thousands of finished units.
Depending on the product and category, development may move through stages such as:
bench/prototype development → pilot batch → testing → stability and packaging compatibility work where required → commercial production
Why? - Because one successful sample does not demonstrate repeatability.
A product can look good. Taste good. Have the desired concentration in one sample.
And still fail commercially because the next batch behaves differently.
The fundamental question is: Can this product be produced repeatedly to an agreed specification?
Testing requirements will depend on the material, formulation and regulatory pathway, but may involve relevant identity, potency/composition, microbiological, contaminant or other quality parameters.
For certain drug-development routes, Indian regulators require extensive characterisation and quality information. CDSCO's phytopharmaceutical framework, for example, emphasises specifications, testing methods and batch consistency.
The larger principle applies beyond pharmaceuticals: If you cannot define the specification, you cannot properly test whether production meets it.
8. Packaging Is Part of Product Development
The bottle, jar, blister or sachet should not be chosen after formulation is finished simply because somebody likes the design. Packaging has functional work to do.
Depending on the product, consider:
light exposure
oxygen and moisture
formula compatibility
closure performance
dose delivery
tamper evidence
child resistance where appropriate
transport conditions
leakage
label area
secondary packaging
shelf presentation
consumer usability
unit economics
For oils, for example, the dropper, pump or dosing system affects the consumer's interaction with the product.
For gummies or other attractive edible formats, packaging decisions also raise obvious household-safety questions.
For products vulnerable to oxidation, light or moisture, the pack may directly influence stability.
Packaging is not decoration added after product development.
It is one of the systems protecting the product.
9. Labelling and Claims: A Compliant Formula Can Still Have Non-Compliant Marketing
This distinction is easy to miss.
What the product contains is one question.
What the company says the product does is another.
FSSAI's hemp-seed rules demonstrate this clearly.
Qualifying hemp-seed foods are subject not only to compositional conditions but also to presentation and labelling restrictions. Among other things, the rules restrict cannabidiol-related nutrient or health claims and certain cannabis imagery.
The same principle should inform every product-development project: Formula → regulatory category → label → website → advertising → marketplace listing → sales material
Those pieces should be aligned before launch.
A carefully developed product can still create problems if the marketing team begins making claims that change how the product is perceived or regulated.
Claims are therefore not just a copywriting decision.
They are a product-development decision.
10. Work Out the Real Economics Before You Manufacture
A product can be technically manufacturable and still be a bad business.
Founders often focus on the manufacturer's quoted unit cost.
That is rarely the whole economic picture.
Your commercial model may need to account for: raw materials + manufacturing + testing + primary packaging + secondary packaging + artwork/compliance + freight + warehousing + regulatory expenses + inventory carrying cost + channel margin + marketing/customer acquisition
That gives you something much closer to the true commercial cost.
Now test that against the MOQ.
A hypothetical example
Assume:
MOQ: 5,000 units
Fully loaded product cost: ₹400/unit
Initial inventory commitment: ₹20 lakh
Retail price: ₹1,200
Channel margin: 35%
Net receipt to brand before marketing: ₹780/unit
Marketing/customer-acquisition allocation: ₹150 per sold unit
That leaves approximately ₹630 per sold unit available to recover the original inventory investment and contribute toward other overheads, under these simplified assumptions.
If all 5,000 units sell:
Net receipts after channel margin = ₹39 lakh
Less original product cost = ₹20 lakh
Less ₹7.5 lakh marketing allocation = ₹11.5 lakh remaining before other business expenses and taxes.
Now consider a weak sell-through case.
If only 2,000 units—40% of the batch—sell:
Cash receipts after channel margin = ₹15.6 lakh
Less marketing allocation on those 2,000 sales = ₹3 lakh
Cash generated from sales so far = ₹12.6 lakh
But the founder originally committed ₹20 lakh to inventory.
The business has therefore not yet recovered approximately ₹7.4 lakh of its original inventory cash commitment, while 3,000 units remain unsold.
Those remaining units still have inventory value. They are not automatically an accounting loss. But they create a different problem: cash is trapped in stock.
Now ask:
How long will those 3,000 units take to sell?
How much shelf life remains?
Will more marketing spend be needed?
Will discounting be required?
Does the company have enough working capital to order the next batch before the first one is cleared?
MOQ is not merely a manufacturing number.
It is a cash-flow decision. Download the Launch Economics worksheet here
Already Selling Overseas? India Still Requires a Fresh Assessment
International companies make another understandable mistake:
“This product is already compliant in Europe/Australia/the UK/the US, so we should be able to launch it in India.”
Foreign compliance does not automatically determine Indian classification or marketability.
An India-entry assessment may need to consider:
finished-product import versus local manufacture
raw-material import versus Indian sourcing
Indian classification of the formulation
ingredient eligibility
formula adaptation
claims adaptation
pack size
pricing architecture
local manufacturing options
distribution model
medical/prescription channel where applicable
local partners
the documentation required for the proposed pathway
For certain drug or phytopharmaceutical products, CDSCO operates its own approval framework rather than simply accepting foreign market status as an Indian marketing authorisation.
Sometimes the correct India strategy may be to import a finished product. Or, it may be to import an ingredient and manufacture locally. Sometimes localisation of the formulation is required.
And sometimes the original overseas product simply does not map cleanly onto the Indian route the company originally expected.
That question should be resolved before inventory is shipped.
Which Type of Founder Are You?
Founder | Typical starting point | What usually needs to be resolved |
First-time entrepreneur | “I have a product idea.” | Product scoping, pathway, development model and manufacturer |
Existing wellness/Ayurvedic company | “We want to add a hemp/cannabis range.” | Classification, formulation, sourcing and manufacturing |
Brand with an existing formula | “We need someone to manufacture it.” | Formula review, raw-material sourcing and manufacturer due diligence |
Overseas company | “We already sell this internationally.” | India classification, import/local-manufacture strategy and localisation |
The starting point changes. The sequence of decisions does not.
Frequently Asked Questions
Can I launch a CBD brand in India?
The answer depends on the actual product, cannabinoid source, intended use, claims and regulatory pathway. “CBD brand” is a commercial description, not by itself a product classification. Start by defining and classifying the product rather than by printing a label or choosing a manufacturer.
Do I need a CBD licence in India?
There is no single universal licence that can simply be described as “the CBD licence” for every business model. Different permissions and regulatory frameworks may apply depending on the substance/material, activity, product category and jurisdiction.
Can I private-label a cannabinoid product in India?
Private labelling does not remove the need for the underlying product, ingredients, manufacturer, label and claims to fit an appropriate lawful pathway. It also does not remove the brand owner's commercial responsibility to understand what it is selling.
How do I find a CBD or hemp manufacturer in India?
Do not start with a list of factories. First define the product, establish its likely classification, write the specification and identify the required manufacturing capabilities. Then compare suitable manufacturers against regulatory fit, technical capability, quality systems, MOQ, documentation, IP terms and economics.
What is the difference between white label and private label?
The terms are used inconsistently. Rather than relying on the terminology, ask what formula you are receiving, whether it can be modified, who owns it, whether it is exclusive, what testing accompanies it and whether you can transfer production elsewhere.
Can hemp products be manufactured under FSSAI?
FSSAI has specifically standardised hemp seeds and qualifying seed products, including hemp seed, hemp-seed oil and hemp-seed flour, subject to prescribed standards and licensing requirements.
That should not be interpreted as blanket food approval for every cannabis- or cannabinoid-derived ingredient.
Can extracted CBD simply be added to food in India?
Do not assume so. FSSAI's hemp-seed framework regulates qualifying hemp seeds and seed products and specifies that cannabinoids in those foods must be naturally present in or on the seeds, alongside other compositional and labelling requirements.
A proposed product containing an extracted cannabinoid requires its own regulatory assessment rather than being assumed to fall within the hemp-seed food standard.
Can an overseas cannabinoid brand enter India?
Potentially, but an overseas product should undergo an India-specific assessment. The regulatory category, ingredients, claims, importability, manufacturing route and commercial model may need to be reconsidered for India.
What documents should I ask a cannabinoid or hemp ingredient supplier for?
The exact package depends on the ingredient and intended use, but you should normally establish specifications, batch COAs, traceability and the quality testing relevant to that material, alongside evidence supporting its lawful and intended supply chain.
How much does it cost to develop a hemp or cannabinoid product in India?
There is no responsible universal figure. Development cost depends on the product category, whether the formula already exists, ingredient complexity, development work, testing, packaging, documentation, regulatory pathway and manufacturer MOQ.
Ask for the cost of the whole launch system, not merely the manufacturer's unit price.
What is a typical MOQ?
It varies enormously by dosage form, manufacturer, ingredient, packaging and whether the product is white label or custom.
The better question is:
What MOQ can my working capital and expected sell-through safely support?
Should I import the finished product or manufacture it in India?
That depends on the product's Indian classification, ingredient availability, import route, manufacturing capability, economics, documentation and launch strategy.
Resolve this early. It can change the entire project structure.
Planning a Hemp or Cannabinoid Product for India? Start Here.
Option 1: Prepare your brief.
Download the Product Brief template covering product format, proposed ingredients or formula, intended consumer and use, target claims, India or international origin, expected volume and MOQ, target selling price, indicative budget, launch timeline and the support you need.
Option 2: Request a Product Pathway Assessment.
A structured review of your concept that identifies what must be resolved before manufacturing begins.
Delta Botanicals & Research supports founders and companies across product scoping, regulatory pathway assessment, formulation and ingredient sourcing, manufacturing-partner identification, packaging and commercial launch planning.
Product first. Pathway second. Manufacturer third.
A factory can make a product. A credible development process determines whether it is the right product to make.
Related reading
This article is intended as general industry and business information and not as legal advice for a specific product. Regulatory requirements can depend on the precise formulation, claims, material, activity and jurisdiction and should be assessed for the individual project before commercial launch.
Comments